Celldex Therapeutics Inc. (NASDAQ:CLDX)’s share price was down 1.1% during trading on Friday . The company traded as low as $4.59 and last traded at $4.60, with a volume of 605,936 shares trading hands. The stock had previously closed at $4.65.

A number of equities analysts have recently commented on CLDX shares. Jefferies Group restated a “hold” rating and issued a $4.00 price objective on shares of Celldex Therapeutics in a research report on Friday, May 6th. Cowen and Company reaffirmed an “outperform” rating and issued a $12.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Roth Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $3.00 target price on shares of Celldex Therapeutics in a research note on Friday, May 6th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $14.11.

The firm has a 50-day moving average of $4.40 and a 200-day moving average of $6.39. The firm’s market capitalization is $458.05 million.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The firm earned $1.30 million during the quarter, compared to analysts’ expectations of $1.06 million. During the same quarter in the previous year, the business earned ($0.33) earnings per share. The company’s revenue for the quarter was up 160.0% compared to the same quarter last year. Analysts anticipate that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Bedell Frazier Investment Counseling LLC boosted its position in shares of Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock valued at $1,023,000 after buying an additional 5,411 shares during the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock valued at $1,151,000 after buying an additional 26,000 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock valued at $1,469,000 after buying an additional 9,072 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock valued at $1,700,000 after buying an additional 5,110 shares during the last quarter. Finally, Numeric Investors LLC purchased a new position in shares of Celldex Therapeutics during the fourth quarter valued at about $1,778,000.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.